To date, many ALK-TKIs have been developed and shown to be effective in NSCLC with epidermal growth factor receptor (EGFR) mutations or ALK rearrangements, leading to the approval of highly potent third-generation TKIs such as Osimertinib and Lorlatinib[9,10] [Table 1]. Here, ALK is linked to non-small cell lung carcinoma.